These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 34145261)

  • 21. Copper and iron ions accelerate the prion-like propagation of α-synuclein: A vicious cycle in Parkinson's disease.
    Li Y; Yang C; Wang S; Yang D; Zhang Y; Xu L; Ma L; Zheng J; Petersen RB; Zheng L; Chen H; Huang K
    Int J Biol Macromol; 2020 Nov; 163():562-573. PubMed ID: 32629061
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Broad neutralization of calcium-permeable amyloid pore channels with a chimeric Alzheimer/Parkinson peptide targeting brain gangliosides.
    Di Scala C; Yahi N; Flores A; Boutemeur S; Kourdougli N; Chahinian H; Fantini J
    Biochim Biophys Acta; 2016 Feb; 1862(2):213-22. PubMed ID: 26655601
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Co-aggregation of pro-inflammatory S100A9 with α-synuclein in Parkinson's disease: ex vivo and in vitro studies.
    Horvath I; Iashchishyn IA; Moskalenko RA; Wang C; Wärmländer SKTS; Wallin C; Gräslund A; Kovacs GG; Morozova-Roche LA
    J Neuroinflammation; 2018 Jun; 15(1):172. PubMed ID: 29866153
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Polyphenols in combination with β-cyclodextrin can inhibit and disaggregate α-synuclein amyloids under cell mimicking conditions: A promising therapeutic alternative.
    Gautam S; Karmakar S; Batra R; Sharma P; Pradhan P; Singh J; Kundu B; Chowdhury PK
    Biochim Biophys Acta Proteins Proteom; 2017 May; 1865(5):589-603. PubMed ID: 28238838
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Insights into the Molecular Mechanisms of Alzheimer's and Parkinson's Diseases with Molecular Simulations: Understanding the Roles of Artificial and Pathological Missense Mutations in Intrinsically Disordered Proteins Related to Pathology.
    Coskuner-Weber O; Uversky VN
    Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29364151
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A sticky situation: Aberrant protein-protein interactions in Parkinson's disease.
    Brown J; Horrocks MH
    Semin Cell Dev Biol; 2020 Mar; 99():65-77. PubMed ID: 29738882
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Amyloid fibrils are the molecular trigger of inflammation in Parkinson's disease.
    Gustot A; Gallea JI; Sarroukh R; Celej MS; Ruysschaert JM; Raussens V
    Biochem J; 2015 Nov; 471(3):323-33. PubMed ID: 26272943
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structure-Based Discovery of Small-Molecule Inhibitors of the Autocatalytic Proliferation of α-Synuclein Aggregates.
    Chia S; Faidon Brotzakis Z; Horne RI; Possenti A; Mannini B; Cataldi R; Nowinska M; Staats R; Linse S; Knowles TPJ; Habchi J; Vendruscolo M
    Mol Pharm; 2023 Jan; 20(1):183-193. PubMed ID: 36374974
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lipid vesicles affect the aggregation of 4-hydroxy-2-nonenal-modified α-synuclein oligomers.
    Sardar Sinha M; Villamil Giraldo AM; Öllinger K; Hallbeck M; Civitelli L
    Biochim Biophys Acta Mol Basis Dis; 2018 Sep; 1864(9 Pt B):3060-3068. PubMed ID: 29960040
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Truncation-Driven Lateral Association of α-Synuclein Hinders Amyloid Clearance by the Hsp70-Based Disaggregase.
    Franco A; Cuéllar J; Fernández-Higuero JÁ; de la Arada I; Orozco N; Valpuesta JM; Prado A; Muga A
    Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884786
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Protein aggregation and neurodegeneration in prototypical neurodegenerative diseases: Examples of amyloidopathies, tauopathies and synucleinopathies.
    Bourdenx M; Koulakiotis NS; Sanoudou D; Bezard E; Dehay B; Tsarbopoulos A
    Prog Neurobiol; 2017 Aug; 155():171-193. PubMed ID: 26209472
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pathological interface between oligomeric alpha-synuclein and tau in synucleinopathies.
    Sengupta U; Guerrero-Muñoz MJ; Castillo-Carranza DL; Lasagna-Reeves CA; Gerson JE; Paulucci-Holthauzen AA; Krishnamurthy S; Farhed M; Jackson GR; Kayed R
    Biol Psychiatry; 2015 Nov; 78(10):672-83. PubMed ID: 25676491
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mechanistic insights into accelerated α-synuclein aggregation mediated by human microbiome-associated functional amyloids.
    Bhoite SS; Han Y; Ruotolo BT; Chapman MR
    J Biol Chem; 2022 Jul; 298(7):102088. PubMed ID: 35654142
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Aggregation Conditions Define Whether EGCG is an Inhibitor or Enhancer of
    Sternke-Hoffmann R; Peduzzo A; Bolakhrif N; Haas R; Buell AK
    Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32183378
    [TBL] [Abstract][Full Text] [Related]  

  • 35. C-terminal truncation exacerbates the aggregation and cytotoxicity of α-Synuclein: A vicious cycle in Parkinson's disease.
    Ma L; Yang C; Zhang X; Li Y; Wang S; Zheng L; Huang K
    Biochim Biophys Acta Mol Basis Dis; 2018 Dec; 1864(12):3714-3725. PubMed ID: 30290273
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Seeking a mechanism for the toxicity of oligomeric α-synuclein.
    Roberts HL; Brown DR
    Biomolecules; 2015 Mar; 5(2):282-305. PubMed ID: 25816357
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alpha-Synuclein Oligomers Interact with Metal Ions to Induce Oxidative Stress and Neuronal Death in Parkinson's Disease.
    Deas E; Cremades N; Angelova PR; Ludtmann MH; Yao Z; Chen S; Horrocks MH; Banushi B; Little D; Devine MJ; Gissen P; Klenerman D; Dobson CM; Wood NW; Gandhi S; Abramov AY
    Antioxid Redox Signal; 2016 Mar; 24(7):376-91. PubMed ID: 26564470
    [TBL] [Abstract][Full Text] [Related]  

  • 38. α-Synuclein: Experimental Pathology.
    Hasegawa M; Nonaka T; Masuda-Suzukake M
    Cold Spring Harb Perspect Med; 2016 Sep; 6(9):. PubMed ID: 27481772
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structural Features and Toxicity of α-Synuclein Oligomers Grown in the Presence of DOPAC.
    Palazzi L; Fongaro B; Leri M; Acquasaliente L; Stefani M; Bucciantini M; Polverino de Laureto P
    Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34199427
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A SUMO1-Derived Peptide Targeting SUMO-Interacting Motif Inhibits α-Synuclein Aggregation.
    Liang Z; Chan HYE; Lee MM; Chan MK
    Cell Chem Biol; 2021 Feb; 28(2):180-190.e6. PubMed ID: 33444530
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.